While a new study found that differences in outcomes from nonmetastatic castration-resistant prostate cancer (nmCRPC) exist based on race and ethnicity, Black and Hispanic men might have considerably improved survival rates when treated in an equal-access setting.
Mast Cell Depletion Affects Prostate Cancer Progression
Better understanding of the cellular immune components underlying aggressive prostate cancer, especially among African American (AA) men who are disproportionately affected by the disease compared with white men, could help improve precision medicine treatment strategies, according to a new study.
VA Study Points Out Need for Transgender Prostate Cancer Awareness
Because of the risks of prostate removal—leakage of urine and problems with sexual function—the prostate usually is left intact in transgender women.
Racial Differences in Prostate Cancer Treatment
How does Health-Related Quality of Life (HRQoL) after treatment of prostate cancer (PCa) differ for patients of different races?
Sexual Issues Common for Partners of PCa Patients
While it is well understood that prostate cancer (PCa) and its treatment can have significant and pervasive sexual side effects for the male patients, less attention has been paid to their partners.
Genetic Scores Might Help Determine Prostate Cancer Risk
Can genetic scores provide an objective measure of prostate cancer risk and aid screening decisions?
Large VA Study Finds Lower Prostate Cancer Screening Rates Associated With Subsequent Increases in Metastatic Cancer
Aside from skin cancer, prostate cancer is the most common cancer among male veterans. When diagnosed at an early stage, prostate cancer is highly curable.
New Tool Estimates Age-Specific Prostate Cancer Risk
A multi-ancestry polygenic risk score (PRS) that stratifies prostate cancer risk across populations has been developed. In a recent study, the developers validated the performance of the PRS in the multi-ancestry Million Veteran Program and additional independent studies.
Survival Rates Better for Prostate Cancer With Radical Prostatectomy
Clinicians haven’t had information on the optimal upfront treatment modality for patients with nonmetastatic Gleason Score 9 and 10 prostate cancer (GS 9-10 PCa).
Second Cancer More Common With Radiotherapy for Prostate Cancer
When men are diagnosed with localized prostate cancer, they are often faced with a difficult decision.
VA Researchers Suggest Non-Hispanic Black Men Might Need More Frequent PSA Screening to Reduce Risk of Prostate Cancer-Specific Mortality
The benefits of annual prostate-specific antigen screening (PSA) appear to vary by race, decreasing the risk of prostate cancer-specific mortality among non-Hispanic Black men but not non-Hispanic white men, according to a new veteran study.
Even With Equal Care, Advanced Prostate Cancer Rates Are Higher for Blacks
DURHAM, NC—Despite its status as the most common cancer in American men, prostate cancer remains significantly understudied in terms of its epidemiology. Previous research has shown a higher risk for prostate cancer overall among Black men, but whether that difference...
Treatment Quandary Continues for Non-metastatic Castration-resistant PCa
While most men with non-metastatic prostate cancer respond to androgen-deprivation therapy initially, many later experience rising prostate-specific antigen levels that indicate they have developed castration resistance.
For Prostate Cancer, Liquid Biopsy Offers New Genomic Profiling Opportunities
Nearly a decade ago, the U.S. Food and Drug Administration approved the first liquid biopsy assay to monitor patients with prostate, breast, and colon cancer by measuring circulating tumor cells (CTC) in patients’ blood.
Study Finds Disparities in VA Prostate Cancer Care
African-American men are disproportionately affected by prostate cancer, but it remains unclear whether racial and ethnic disparities occur in equal-access settings at the national level.
Military, Veterans More Likely to Be Screened for Many Types of Cancer
While some cancer diagnoses are disproportionately high among VA patients, the cause does not appear to be inadequate screening, according to a new study.
Military, Veterans More Likely to Get Most Cancer Screening
While cancer diagnoses are disproportionately high among VA patients, the cause does not appear to be inadequate screening, according to a new study.
How PSA Testing Affects Prostate Cancer in Young African-American Men
Younger African-American men are at high risk of prostate cancer but tend to be underrepresented in clinical trials related to prostate-specific antigen (PSA) levels, according to a new study.
Clinical Implications of Risk Stratification in Prostate Cancer
Low-volume, nonlocalized prostate cancer that was occult on conventional imaging often can be detected with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT).
Does Prostate Size Matter for Cancer Surgery Outcomes?
How does the size of prostates affect outcomes from prostate cancer surgery.
For Veterans With Prostate Cancer, Treatment Can Damage Heart Health
It’s long been said that “more men die with prostate cancer than from it.” While the statement remains true today, what treatment they receive appears to influence the cause of death.
What Affects Acute Pain After Breast Cancer Surgery?
Acute postoperative pain following surgery can complicate recovery, according to a study which said the condition has been associated with chronic pain development and lower quality of life.
Monocyte Counts Aren’t Predictive of Prostate Cancer Results
How effective are circulating inflammatory markers such as monocyte counts for predicting prostate cancer outcomes? Not very, according to a study of veterans.
Prostate Cancer, Treatment Causes Financial Strain for Veterans
Not all of the damage caused by prostate cancer is to men’s bodies.
Enhanced Imaging Changes Prostate Cancer Treatment at VA
Prostate-specific membrane antigen (PSMA) ligands offer a strategy to develop prostate-specific positron emission tomography tracers, which can significantly heighten the accuracy of systemic prostate cancer imaging, according to a new study.
New Study Reviews Emerging Novel Therapies for mCRPC
Novel therapies are being investigated for metastatic castration resistant prostate cancer, according to a new review.
Prostate-Specific Antigen Doubling Time Helps Determine Prognosis at VHA
What is the association between prostate-specific antigen doubling time (PSADT) with metastasis-free survival (MFS) and overall survival (OS) in VHA patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC)?
VHA PSA Screening Rates Dropped for Some Groups
How did the 2012 U.S. Preventive Services Task Force recommendation against the prostate specific antigen screening for prostate cancer affect practice at the VHA?
Statin Effect on Death in Veterans With Prostate Cancer
SAN ANTONIO — As the most common cancer in men in the United States, prostate cancer is associated with a prolonged survival and patient care often includes optimizing other comorbidities, such as cardiovascular disease.
Prognostic Models Fail to Reflect Racial Differences in Prostate Cancer
Every physician knows each patient is different. Prognostic models, however, tend to assume everyone’s the same. That can skew decisions in cancer care.